Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer therapies in the United States. The company`s product pipeline includes, AB928, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 monoclonal antibody that is in Phase Ib clinical trial for monotherapy. It is also developing AB154, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab and AB928; and AB680, small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer. Arcus Biosciences, Inc. has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca to evaluate domvanalimab (AB154), its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics (Cayman) Inc. The company was founded in 2015 and is based in Hayward, California.
Website: arcusbio.com



Growth: Bad revenue growth rate -8.8%, there is slowdown compared to average historical growth rates 79.6%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -286.3%. On average the margin is decreasing steadily. Gross margin is high, +83.9%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -30.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 20.3% higher than minimum and 66.7% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -9.7x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $2.2 mln (-0.202% of cap.)

Key Financials (Download financials)

Ticker: RCUS
Share price, USD:  (+5.8%)16.15
year average price 17.90  


year start price 18.48 2023-05-12

max close price 23.54 2023-07-12

min close price 13.43 2023-11-13

current price 16.15 2024-05-10
Common stocks: 54 787 118

Dividend Yield:  0.0%
Last revenue growth (y/y):  -8.8%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  79.6%
Historical growth of EBITDA:  -10.5%
EV / Sales: 0.2x
Margin (EBITDA LTM / Revenue): -286.3%
Fundamental value created in LTM:
Market Cap ($m): 885
Net Debt ($m): -866
EV (Enterprise Value): 19
Price to Book: 1.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-05-08Seeking Alpha

Arcus Biosciences, Inc. (RCUS) Q1 2024 Earnings Call Transcript

2024-05-08Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

2024-05-01Zacks Investment Research

Will Arcus Biosciences, Inc. (RCUS) Report Negative Earnings Next Week? What You Should Know

2024-02-28Business Wire

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

2024-02-22Zacks Investment Research

Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet

2024-02-22Seeking Alpha

Arcus Biosciences, Inc. (RCUS) Q4 2023 Earnings Call Transcript

2023-12-15Seeking Alpha

Arcus Biosciences: Showing There Might Be Something To TIGIT After All

2023-11-08Seeking Alpha

Arcus Biosciences, Inc. (RCUS) Q3 2023 Earnings Call Transcript

2023-08-07Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates

2023-05-09Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RCUS RCUS RCUS RCUS RCUS RCUS RCUS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-08 2024-02-21 2023-11-07 2023-08-07 2023-05-09 2023-02-28 2022-11-02
acceptedDate 2024-05-08 16:08:38 2024-02-21 16:16:29 2023-11-07 16:11:43 2023-08-07 08:13:27 2023-05-09 16:15:52 2023-02-28 16:18:59 2022-11-02 16:11:59
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 145M 31M 32M 29M 25M 345 000 34M
costOfRevenue 0 5M 3M 0 0 0 0
grossProfit 145M 26M 29M 29M 25M 345 000 34M
grossProfitRatio 1.000 0.839 0.906 1.000 1.000 1.000 1.000
researchAndDevelopmentExpenses 109M 93M 82M 84M 81M 80M 77M
generalAndAdministrativeExpenses 32M 29M 30M 28M 30M 28M 26M
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 32M 29M 30M 28M 30M 28M 26M
otherExpenses 20M 0 0 0 0 0 0
operatingExpenses 161M 122M 112M 112M 111M 108M 103M
costAndExpenses 161M 122M 112M 112M 111M 108M 103M
interestIncome 0 11M 12M 9M 9M 8M 5M
interestExpense 0 -2M 1 000 000 0 1 000 000 1 000 000 535 000
depreciationAndAmortization 0 3M 12M 2M 9M 8M 7M
ebitda -16M -77M -68M -74M -77M -66M -63M
ebitdaratio -0.110 -2.484 -2.125 -2.552 -3.080 -191.304 -1.871
operatingIncome -16M -91M -80M -83M -86M -74M -69M
operatingIncomeRatio -0.110 -2.935 -2.500 -2.862 -3.440 -214.493 -2.067
totalOtherIncomeExpensesNet 12M 11M 11M 9M 8M 7M 4M
incomeBeforeTax -4M -80M -69M -74M -78M -67M -65M
incomeBeforeTaxRatio -0.028 -2.581 -2.156 -2.552 -3.120 -194.203 -1.933
incomeTaxExpense 0 1 000 000 2M 1 000 000 2M -4000.000 -4M
netIncome -4M -81M -71M -75M -80M -67M -60M
netIncomeRatio -0.028 -2.613 -2.219 -2.586 -3.200 -194.191 -1.800
eps -0.046 -1.080 -0.950 -1.020 -1.100 -0.920 -0.840
epsdiluted -0.046 -1.080 -0.950 -1.020 -1.100 -0.920 -0.840
weightedAverageShsOut 86M 75M 75M 73M 73M 73M 72M
weightedAverageShsOutDil 86M 75M 75M 73M 73M 73M 72M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RCUS RCUS RCUS RCUS RCUS RCUS RCUS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-08 2024-02-21 2023-11-07 2023-08-07 2023-05-09 2023-02-28 2022-11-02
acceptedDate 2024-05-08 16:08:38 2024-02-21 16:16:29 2023-11-07 16:11:43 2023-08-07 08:13:27 2023-05-09 16:15:52 2023-02-28 16:18:59 2022-11-02 16:11:59
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 185M 127M 184M 230M 238M 206M 218M
shortTermInvestments 810M 632M 615M 700M 716M 803M 831M
cashAndShortTermInvestments 995M 759M 950M 1 010M 1 044M 1 138M 1 049M
netReceivables 0 42M 56M 37M 36M 43M 31M
inventory 0 0 -207M -80M -90M -172M 0
otherCurrentAssets 69M 30M 83M 19M 25M 58M 22M
totalCurrentAssets 1 064M 831M 882M 986M 1 015M 1 067M 1 101M
propertyPlantEquipmentNet 51M 51M 50M 45M 37M 35M 136M
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 100M 107M 151M 80M 90M 129M 143M
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 78M 106M 108M 109M 112M 114M 14M
totalNonCurrentAssets 229M 264M 309M 234M 239M 278M 293M
otherAssets 0 0 0 0 0 0 0
totalAssets 1 293M 1 095M 1 191M 1 220M 1 254M 1 345M 1 394M
accountPayables 16M 17M 17M 12M 28M 20M 11M
shortTermDebt 0 11M 9M 57M 0 0 0
taxPayables 0 0 3M 2M 1 000 000 0 18 000
deferredRevenue 124M 91M 103M 103M 97M 97M 103M
otherCurrentLiabilities 64M 65M 71M 8M 54M 76M 63M
totalCurrentLiabilities 204M 184M 200M 180M 179M 193M 177M
longTermDebt 0 110M 115M 0 0 0 119M
deferredRevenueNonCurrent 242M 307M 326M 330M 330M 355M 383M
deferredTaxLiabilitiesNonCurrent 0 -110M -115M 0 0 0 0
otherNonCurrentLiabilities 140M 142M 145M 144M 145M 140M 404M
totalNonCurrentLiabilities 382M 449M 471M 474M 475M 495M 518M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 0 11M 9M 0 0 0 119M
totalLiabilities 586M 633M 671M 654M 654M 688M 695M
preferredStock 0 0 0 0 0 0 0
commonStock 1 561M 1 311M 1 291M 1 267M 1 226M 1 206M 7000.000
retainedEarnings -853M -849M -768M -697M -622M -542M -475M
accumulatedOtherComprehensiveIncomeLoss -1 000 000 0 -3M -4M -4M -7M -10M
othertotalStockholdersEquity 0 0 0 0 0 0 1 183M
totalStockholdersEquity 707M 462M 520M 566M 600M 657M 699M
totalEquity 707M 462M 520M 566M 600M 657M 699M
totalLiabilitiesAndStockholdersEquity 1 293M 1 095M 1 191M 1 220M 1 254M 1 345M 1 394M
minorityInterest 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 293M 1 095M 1 191M 1 220M 1 254M 1 345M 1 394M
totalInvestments 910M 739M 766M 780M 806M 932M 974M
totalDebt 0 11M 9M 0 0 0 119M
netDebt -185M -116M -175M -230M -238M -206M -98M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol RCUS RCUS RCUS RCUS RCUS RCUS RCUS
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-05-08 2024-02-21 2023-11-07 2023-08-07 2023-05-09 2023-02-28 2022-11-02
acceptedDate 2024-05-08 16:08:38 2024-02-21 16:16:29 2023-11-07 16:11:43 2023-08-07 08:13:27 2023-05-09 16:15:52 2023-02-28 16:18:59 2022-11-02 16:11:59
calendarYear 2024.000 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -4M -81M -71M -75M -80M -67M -65M
depreciationAndAmortization 3M 3M 1 000 000 2M 2M 1M 2M
deferredIncomeTax 0 16M -29M 13M 0 0 0
stockBasedCompensation 20M 18M 18M 18M 19M 17M 16M
changeInWorkingCapital 0 -24M -9M -13M -38M -21M -35M
accountsReceivables 0 -11M 11M 0 0 -7M 7M
inventory 0 -6M 6M 0 0 0 0
accountsPayables -1 000 000 2M 6M -19M 10M 8M -12M
otherWorkingCapital 0 -9M -32M 19M -48M -22M -30M
otherNonCashItems 0 -20M 27M -2M -1 000 000 252 000 966 000
netCashProvidedByOperatingActivities -2M -88M -63M -57M -98M -70M -81M
investmentsInPropertyPlantAndEquipment -4M -6M -10M -5M -3M -880 000 -1M
acquisitionsNet 0 21M -21M 0 0 0 0
purchasesOfInvestments -387M -115M -280M -239M -154M -156M -322M
salesMaturitiesOfInvestments 222M 149M 301M 270M 286M 203M 344M
otherInvestingActivites 0 -21M 21M 0 0 250 000 3M
netCashUsedForInvestingActivites -169M 28M 11M 26M 129M 47M 23M
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 228M 3M 10M 19M 1 000 000 23M 0
commonStockRepurchased 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 1 000 000 8M -4M 4M 0 -12M 3M
netCashUsedProvidedByFinancingActivities 229M 3M 6M 23M 1 000 000 11M 3M
effectOfForexChangesOnCash 0 -26M 0 26M 0 81 000 0
netChangeInCash 58M -57M -46M -8M 32M -12M -55M
cashAtEndOfPeriod 188M 130M 187M 233M 241M 209M 221M
cashAtBeginningOfPeriod 130M 187M 233M 241M 209M 221M 276M
operatingCashFlow -2M -88M -63M -57M -98M -70M -81M
capitalExpenditure -4M -6M -10M -5M -3M -880 000 -1M
freeCashFlow -6M -94M -73M -62M -101M -71M -82M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q1
2024-05-08 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-08 ET (fiscal 2023 q3)

Press-releases

Show financial reports only

2024-05-09 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-05-08 20:02 ET
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
2024-05-02 20:05 ET
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
2024-04-24 20:00 ET
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
2024-04-23 20:05 ET
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
2024-04-09 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-03-26 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-03-11 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-02-28 21:05 ET
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
2024-02-27 21:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-02-21 21:05 ET
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
2024-02-09 21:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-02-07 22:00 ET
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates
2024-01-29 22:00 ET
Gilead and Arcus Announce Amended Collaboration and Equity Investment
2024-01-26 21:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2024-01-16 22:00 ET
Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer
2023-12-11 21:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-12-04 13:00 ET
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
2023-11-27 21:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-11-14 21:00 ET
Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference
2023-11-13 21:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-11-07 21:01 ET
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
2023-11-06 22:00 ET
Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers
2023-10-24 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-10-17 20:00 ET
Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7
2023-10-10 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-09-26 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-09-11 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-08-24 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-08-23 13:00 ET
Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences
2023-08-09 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-08-07 12:00 ET
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
2023-07-25 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-07-11 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-06-26 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-06-09 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-06-03 17:30 ET
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
2023-05-30 20:00 ET
Arcus Biosciences to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
2023-05-24 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-05-17 12:30 ET
Presentations at the 2023 ASCO Annual Meeting Highlight Arcus Biosciences’ Expanding Portfolio of Investigational Medicines and Late-Stage Studies Across Multiple Types of Cancer
2023-05-15 12:30 ET
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
2023-05-09 20:05 ET
Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update
2023-05-08 20:35 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-04-25 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-04-11 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-03-09 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-03-02 21:00 ET
Arcus Biosciences to Participate in the Barclays Global Healthcare Conference
2023-02-28 21:05 ET
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides a Pipeline Update
2023-02-24 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-02-09 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-02-06 21:05 ET
Arcus Biosciences to Participate at Upcoming Virtual Investor Events
2023-01-24 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2023-01-10 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-12-24 01:00 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-12-19 22:00 ET
Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study
2022-12-09 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-11-28 13:30 ET
Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer
2022-11-24 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-11-14 21:05 ET
Arcus Biosciences to Participate in the 5th Annual Evercore ISI HealthCONx Conference
2022-11-09 21:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-11-02 20:02 ET
Arcus Biosciences Reports Third Quarter 2022 Financial Results and Provides a Pipeline Update
2022-10-25 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-10-11 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-09-26 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-09-09 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-08-24 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-08-24 20:05 ET
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
2022-08-09 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-08-08 20:05 ET
Arcus Biosciences Appoints Dimitry Nuyten, M.D., Ph.D. as Chief Medical Officer
2022-08-03 20:03 ET
Arcus Biosciences Reports Second Quarter 2022 Financial Results and Provides a Pipeline Update
2022-07-27 20:01 ET
Arcus Biosciences to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference
2022-07-26 20:05 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-07-11 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-06-24 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-06-09 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-05-31 20:05 ET
Arcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-05-24 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-05-10 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-05-09 20:03 ET
Arcus Biosciences Reports First Quarter 2022 Financial Results and Provides a Pipeline Update, Including from the Third Interim Analysis for the ARC-7 Study
2022-04-26 20:30 ET
Arcus Biosciences to Report First Quarter 2022 Financial Results and Pipeline Update
2022-04-26 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-04-11 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-04-04 22:45 ET
Arcus Biosciences Set to Join S&P SmallCap 600
2022-03-24 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-03-09 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-03-08 21:30 ET
Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences
2022-02-24 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-02-23 21:05 ET
Arcus Biosciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
2022-02-15 21:10 ET
Arcus Biosciences to Participate in the Upcoming Investor Conferences
2022-02-09 22:04 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-01-25 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-01-11 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2022-01-10 13:00 ET
Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones
2021-12-24 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-12-21 21:35 ET
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
2021-12-09 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-11-30 06:00 ET
Taiho Pharmaceutical Exercises Option for an Exclusive License to Arcus Biosciences’ Anti-TIGIT Program in Japan and Certain Territories in Asia
2021-11-24 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-11-22 21:10 ET
Arcus Biosciences to Participate in the Upcoming Evercore ISI HealthCONx 2021 Conference
2021-11-18 12:00 ET
Gilead Exercises Options to Three Arcus Biosciences Clinical-Stage Programs and Adds Research Collaboration
2021-11-09 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-11-08 21:10 ET
Arcus Biosciences Reports Third Quarter 2021 Financial Results and Provides an Update on our anti-TIGIT Domvanalimab
2021-11-02 20:10 ET
Arcus Biosciences to Report Third Quarter 2021 Financial Results & Recent Corporate Highlights
2021-10-26 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-10-11 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-09-27 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-09-09 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-09-01 20:10 ET
Arcus Biosciences to Participate at Upcoming Investor Conferences
2021-08-24 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-08-10 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-08-05 20:10 ET
Arcus Biosciences Reports Second Quarter 2021 Financial Results and Provides Operational Highlights
2021-08-04 20:10 ET
Arcus Biosciences to Participate at the 2021 Wedbush PacGrow Virtual Healthcare Conference
2021-07-29 20:10 ET
Arcus Biosciences to Report Second Quarter 2021 Financial Results & Recent Corporate Highlights
2021-07-26 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-07-12 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-06-24 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-06-23 20:10 ET
Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences’ Randomized Phase 2 ARC-7 Study
2021-06-09 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-05-25 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-05-19 21:05 ET
Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting
2021-05-11 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-05-05 20:10 ET
Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights
2021-04-26 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-04-10 12:33 ET
Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
2021-04-09 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-03-24 20:15 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-03-09 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-02-25 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-02-24 21:10 ET
Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights
2021-02-11 21:10 ET
Arcus Biosciences to Participate in Upcoming Investor Conferences
2021-02-09 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-02-01 13:00 ET
Gilead Sciences to Increase Its Ownership In Arcus Biosciences
2021-01-26 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-01-15 13:03 ET
Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer
2021-01-12 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2021-01-11 22:03 ET
Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium
2021-01-06 21:10 ET
Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead’s SVP of Research Biology, Michael Quigley, Ph.D. to Its Board of Directors
2020-12-10 21:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-12-10 00:30 ET
Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer
2020-11-18 21:10 ET
Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference
2020-11-10 22:30 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-11-05 21:10 ET
Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates
2020-10-29 10:59 ET
Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus’s Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC
2020-10-08 21:00 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-10-01 20:41 ET
Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer
2020-09-10 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-08-27 20:10 ET
Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences
2020-08-11 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-08-06 20:10 ET
Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates
2020-08-04 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grant
2020-07-28 20:10 ET
Arcus Biosciences to Participate in Upcoming August Investor Conferences
2020-07-13 20:05 ET
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
2020-07-09 20:15 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-07-07 20:10 ET
Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer
2020-06-09 20:10 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-06-03 20:10 ET
Arcus Biosciences to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
2020-05-29 02:37 ET
Arcus Biosciences, Inc. Announces Pricing of $302.5 Million Underwritten Public Offering of Common Stock
2020-05-27 20:46 ET
Arcus Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
2020-05-26 20:10 ET
Arcus Biosciences Appoints David Lacey, M.D., to Its Board of Directors
2020-05-11 20:15 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-05-05 20:10 ET
Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates
2020-04-09 20:30 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-03-11 12:00 ET
Arcus Biosciences Announces New Employment Inducement Grants
2020-03-05 21:10 ET
Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
2020-02-26 13:00 ET
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries
2020-02-12 21:10 ET
Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2019-12-18 21:05 ET
Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers
2019-12-12 14:00 ET
Arcus Biosciences Appoints Patrick Machado, J.D., to its Board of Directors
2019-11-05 21:15 ET
Arcus Biosciences Announces Third Quarter 2019 Financial Results and Recent Corporate Updates

SEC forms

Show financial reports only

SEC form 10
2024-02-21 16:16 ET
Arcus Biosciences published news for 2023 q4
SEC form 8
2024-02-21 16:08 ET
Arcus Biosciences published news for 2023 q4
SEC form 8
2024-02-21 16:08 ET
Arcus Biosciences reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
Arcus Biosciences published news for 2023 q4
SEC form 10
2023-11-07 16:11 ET
Arcus Biosciences reported for 2023 q3
SEC form 8
2023-11-07 16:04 ET
Arcus Biosciences published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Arcus Biosciences published news for 2023 q3
SEC form 10
2023-08-07 08:13 ET
Arcus Biosciences reported for 2023 q2
SEC form 6
2023-08-07 08:08 ET
Arcus Biosciences published news for 2023 q2
SEC form 10
2023-08-07 00:00 ET
Arcus Biosciences published news for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Arcus Biosciences published news for 2023 q2
SEC form 6
2023-06-28 08:25 ET
Arcus Biosciences published news for 2023 q1
SEC form 6
2023-06-16 16:19 ET
Arcus Biosciences published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Arcus Biosciences published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Arcus Biosciences published news for 2023 q1
SEC form 6
2023-03-10 16:46 ET
Arcus Biosciences published news for 2022 q4
SEC form 10
2023-02-28 16:18 ET
Arcus Biosciences reported for 2022 q4
SEC form 6
2023-02-28 16:11 ET
Arcus Biosciences published news for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Arcus Biosciences reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Arcus Biosciences reported for 2022 q4
SEC form 6
2022-12-19 17:05 ET
Arcus Biosciences published news for 2022 q3
SEC form 6
2022-11-28 08:39 ET
Arcus Biosciences published news for 2022 q3
SEC form 10
2022-11-02 16:11 ET
Arcus Biosciences reported for 2022 q3
SEC form 6
2022-11-02 16:05 ET
Arcus Biosciences published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Arcus Biosciences reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Arcus Biosciences reported for 2022 q3
SEC form 6
2022-10-11 16:13 ET
Arcus Biosciences published news for 2022 q3
SEC form 10
2022-08-03 16:22 ET
Arcus Biosciences reported for 2022 q2
SEC form 6
2022-08-03 16:16 ET
Arcus Biosciences published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Arcus Biosciences reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Arcus Biosciences reported for 2022 q2
SEC form 6
2022-06-16 16:14 ET
Arcus Biosciences published news for 2022 q1
SEC form 10
2022-05-09 16:15 ET
Arcus Biosciences reported for 2022 q1
SEC form 6
2022-05-09 16:08 ET
Arcus Biosciences published news for 2022 q1
SEC form 10
2022-05-09 00:00 ET
Arcus Biosciences reported for 2022 q1
SEC form 8
2022-05-09 00:00 ET
Arcus Biosciences reported for 2022 q1
SEC form 6
2022-04-20 16:12 ET
Arcus Biosciences published news for 2022 q1
SEC form 10
2022-02-23 16:16 ET
Arcus Biosciences published news for 2021 q4
SEC form 6
2022-02-23 16:08 ET
Arcus Biosciences published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Arcus Biosciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Arcus Biosciences published news for 2021 q4
SEC form 6
2021-12-21 16:40 ET
Arcus Biosciences published news for 2021 q3
SEC form 6
2021-11-18 07:06 ET
Arcus Biosciences published news for 2021 q3
SEC form 6
2021-11-08 17:11 ET
Arcus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 16:16 ET
Arcus Biosciences published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Arcus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Arcus Biosciences published news for 2021 q3
SEC form 6
2021-08-11 16:33 ET
Arcus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 16:19 ET
Arcus Biosciences published news for 2021 q2
SEC form 6
2021-08-05 16:13 ET
Arcus Biosciences published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Arcus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Arcus Biosciences published news for 2021 q2
SEC form 6
2021-07-19 16:47 ET
Arcus Biosciences published news for 2021 q2
SEC form 6
2021-06-07 16:26 ET
Arcus Biosciences published news for 2021 q1
SEC form 10
2021-05-05 16:19 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-05-05 16:13 ET
Arcus Biosciences published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Arcus Biosciences published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-04-26 16:24 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-04-20 16:09 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-04-16 19:02 ET
Arcus Biosciences published news for 2021 q1
SEC form 6
2021-03-16 16:06 ET
Arcus Biosciences published news for 2020 q4
SEC form 10
2021-02-24 19:10 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2021-02-24 16:13 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2021-02-01 08:08 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2021-01-06 16:15 ET
Arcus Biosciences published news for 2020 q4
SEC form 6
2020-12-18 16:13 ET
Arcus Biosciences published news for 2020 q3
SEC form 10
2020-11-05 16:25 ET
Arcus Biosciences published news for 2020 q3
SEC form 6
2020-11-05 16:16 ET
Arcus Biosciences published news for 2020 q3
SEC form 6
2020-10-01 16:50 ET
Arcus Biosciences published news for 2020 q3